ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Prophylactic and therapeutic effects of aspirin in cancer.
Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Aspirin (acetylsalicylic acid) is the oldest synthetic drug and is recognized for its analgesic, antipyretic, antiplatelet effects, and mediators in inflammation. The available research evidence shows that aspirin prevents precursor lesions and cancers, and has therapeutic properties against certain cancer types. This review explores the pharmacological properties of low-dose aspirin related to its preventive effects on cancer, emphasizing the possible mechanisms of action involved in cancer control. It discusses the modulation of signaling pathways related to inflammation, regulation of the cell cycle and apoptosis, inhibition of angiogenesis associated with tumor growth, inhibition of metastasis, and regulation of the immune response. Furthermore, aspirin could be a very promising drug for adjuvant treatment in cancer patients and with implications in the prevention of certain types of cancer.
Indexed as
Identifiers
42747715What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.